ASGR1 and metabolic dysfunction-associated steatohepatitis: The data presented in a recent study by Povero et al. [46] indicated that EVs expressing ASGR1 comprise approximately 20% of the circulating global pool and that the number of hepatocyte-derived EVs increases with severity of NASH.